These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35998555)

  • 1. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
    Goldenberg RM
    J Diabetes Complications; 2022 Sep; 36(9):108285. PubMed ID: 35998555
    [No Abstract]   [Full Text] [Related]  

  • 2. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
    Liu Y; Tian Q; Yang J; Wang H; Hong T
    Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.
    Bellastella G; Maiorino MI; Longo M; Scappaticcio L; Chiodini P; Esposito K; Giugliano D
    Stroke; 2020 Feb; 51(2):666-669. PubMed ID: 31813360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.
    Patoulias D; Papadopoulos C; Kassimis G; Karagiannis A; Doumas M
    Am J Cardiol; 2021 Nov; 159():143-146. PubMed ID: 34497008
    [No Abstract]   [Full Text] [Related]  

  • 5. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
    Yoshida Y; Joshi P; Barri S; Wang J; Corder AL; O'Connell SS; Fonseca VA
    J Diabetes Complications; 2022 Aug; 36(8):108255. PubMed ID: 35817678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases].
    Gilarevsky SR
    Kardiologiia; 2021 May; 61(4):66-72. PubMed ID: 33998411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Pulipati VP; Ravi V; Pulipati P
    Eur J Prev Cardiol; 2020 Dec; 27(18):1922-1930. PubMed ID: 32089007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.
    Al-Kindi SG; Janus SE; Neeland IJ; Rajagopalan S
    J Diabetes Complications; 2022 Jul; 36(7):108224. PubMed ID: 35667964
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The early use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk].
    Nardi F; Di Fusco SA; Spinelli A; Aquilani S; Riccio C; Caldarola P; De Luca L; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Apr; 24(4):285-292. PubMed ID: 36971172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.
    Qian W; Liu F; Yang Q
    J Clin Pharm Ther; 2021 Dec; 46(6):1650-1658. PubMed ID: 34355405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.
    Vaduganathan M; Patel RB; Singh A; McCarthy CP; Qamar A; Januzzi JL; Scirica BM; Butler J; Cannon CP; Bhatt DL
    J Am Coll Cardiol; 2019 Apr; 73(12):1596-1598. PubMed ID: 30922481
    [No Abstract]   [Full Text] [Related]  

  • 18. Making sense of newer treatment options for type 2 diabetes.
    Lee PC; Hare MJL; Bach LA
    Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
    Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
    Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.
    Salem AM; Bain SC; Obaid DR
    Atherosclerosis; 2022 Jul; 352():83-84. PubMed ID: 35662526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.